Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Assembly Biosciences Inc. (ASMB) Insider Trading Activity

    Healthcare • Biotechnology • 65 employees

    Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

    Total Value

    $20,519,803.98

    Total Shares

    968,661

    Average Trade Value

    $3,419,967.33

    Most Active Insider

    Gilead Sciences, Inc.

    Total Activity: $20,098,464

    Largest Single Transaction

    $20,098,464

    by Gilead Sciences, Inc. on Dec 19, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Dec 30, 2024 3,202 $49,998 3,202 (+100.0%) Purchase
    10% Owner
    Dec 19, 2024 940,499 $20,098,464 2,209,471 (+42.6%) Purchase
    10% Owner
    Nov 25, 2024 5,000 $74,250 728,113 (+0.7%) Purchase
    10% Owner
    Nov 25, 2024 2,976 $44,640 723,113 (+0.4%) Purchase
    10% Owner
    Nov 22, 2024 17,024 $253,104 720,137 (+2.4%) Purchase
    Chief Manufacturing Officer
    Nov 18, 2024 40 $652 11,871 (-0.3%) Sale